Objective "The HIV pandemic continues to be a worldwide public-health problem. The virus, which is spread through sexual contact, exposure to infected blood, or through shared syringes, is highly infective, rapidly mutates, and has no cure. Because there is no effective vaccine or other prophylaxis available, the current best practice and standard of care for those infected is an early, accurate diagnosis for the presence of HIV followed by immediate treatment on antiretroviral therapies and counseling. The most commonly used and widely accessible diagnostic tests and assays rely on the presence of HIV antibodies, but the window period before seroconversion takes place to produce these antibodies in the host can take up to six months. Moreover, newborns cannot be tested with these methods due to maternal antibodies masking their true HIV status. Thus, antibody-detecting approaches have major shortcomings in incidence and infant testing, which are critical components to early treatment and reduced transmission rates. Diagnostic tests targeting antibodies or nucleic acids are also susceptible to false or discordant results due to viral variations.Hence, of particular interest as a target then is the conserved viral capsid protein, p24 antigen. Under certain conditions, antigen assays can achieve sensitivities that nearly match those of NATs without the need for amplification steps, and the antigen has a much shorter window period than the antibody, allowing it to be much more effective at incidence and infant testing." Fields of science engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensorsbiosensorsnatural sciencesbiological sciencesbiochemistrybiomoleculesnucleic acidsmedical and health scienceshealth sciencespublic healthepidemiologypandemicsmedical and health scienceshealth sciencesinfectious diseasesRNA virusesHIVmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines Programme(s) FP7-SME - Specific Programme "Capacities": Research for the benefit of SMEs Topic(s) SME-2011-1 - Research for SMEs Call for proposal FP7-SME-2011 See other projects for this call Funding Scheme BSG-SME - Research for SMEs Coordinator ATEKNEA SOLUTIONS HUNGARY KFT EU contribution € 39 460,00 Address TETENYI UT 93 1119 BUDAPEST Hungary See on map Region Közép-Magyarország Budapest Budapest Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Attila Uderszky (Mr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data Participants (6) Sort alphabetically Sort by EU Contribution Expand all Collapse all CAPSENZE HANDELSBOLAG Sweden EU contribution € 236 600,00 Address SCHEELEVAGEN 22 223 63 LUND See on map Region Södra Sverige Sydsverige Skåne län Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Martin Hedström (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data PHENOSYSTEMS SA Switzerland EU contribution € 169 720,00 Address SENTIER DES COMMUNS 1 1807 BLONAY See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact David Atlan (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data LIONEX GMBH Germany EU contribution € 272 720,00 Address Salzdahlumer Strasse 196 38126 Braunschweig See on map Region Niedersachsen Braunschweig Braunschweig, Kreisfreie Stadt Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Mahavir Singh (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data AB BCN SL Spain EU contribution € 194 330,00 Address LG BELLATERRA PARC DE RECERCA UAB CAMPUS UNI UAB 08193 CERDANYOLA DEL VALLES See on map Region Este Cataluña Barcelona Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Marina Azor Alastuey (Ms.) Links Contact the organisation Opens in new window Total cost No data FIMA SRL Participation ended Italy EU contribution No data Address VIA A VANZETTI 43 05100 TERNI See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Elisabetta Mauri (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data MAX IV Laboratory, Lund University Sweden EU contribution € 23 670,00 Address Paradisgatan 5c 22100 LUND See on map Region Södra Sverige Sydsverige Skåne län Activity type Higher or Secondary Education Establishments Administrative Contact Maria Andersson (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data
